MA46341A - Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 - Google Patents
Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5Info
- Publication number
- MA46341A MA46341A MA046341A MA46341A MA46341A MA 46341 A MA46341 A MA 46341A MA 046341 A MA046341 A MA 046341A MA 46341 A MA46341 A MA 46341A MA 46341 A MA46341 A MA 46341A
- Authority
- MA
- Morocco
- Prior art keywords
- monocyclic
- cyclic
- new
- bicyclic system
- prmt5 inhibitors
- Prior art date
Links
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title 1
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403336P | 2016-10-03 | 2016-10-03 | |
| EP17157785 | 2017-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46341A true MA46341A (fr) | 2019-08-07 |
Family
ID=60043171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046341A MA46341A (fr) | 2016-10-03 | 2017-10-02 | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11098062B2 (https=) |
| EP (1) | EP3519413A1 (https=) |
| JP (2) | JP7101171B2 (https=) |
| KR (1) | KR102531344B1 (https=) |
| CN (2) | CN115626935B (https=) |
| AU (1) | AU2017338269B2 (https=) |
| BR (1) | BR112019006414A2 (https=) |
| CA (1) | CA3037998A1 (https=) |
| IL (1) | IL265718B (https=) |
| MA (1) | MA46341A (https=) |
| MX (2) | MX2019003843A (https=) |
| PE (1) | PE20190706A1 (https=) |
| PH (1) | PH12019500731A1 (https=) |
| TN (1) | TN2019000087A1 (https=) |
| UA (1) | UA124074C2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| CN115626935B (zh) | 2016-10-03 | 2025-07-15 | 詹森药业有限公司 | 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物 |
| CN110382707A (zh) | 2017-02-27 | 2019-10-25 | 詹森药业有限公司 | 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途 |
| IL275129B2 (en) | 2017-12-08 | 2023-10-01 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
| WO2019219805A1 (en) * | 2018-05-16 | 2019-11-21 | Ctxone Pty Ltd | Combination therapy |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| WO2021055797A1 (en) * | 2019-09-18 | 2021-03-25 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US20230066014A1 (en) * | 2019-12-03 | 2023-03-02 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| CN113186153B (zh) * | 2021-04-15 | 2023-09-08 | 南方医科大学 | Prmt5抑制剂在促进精原干细胞损伤再生和增殖中的应用 |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
| CN114740108B (zh) * | 2022-03-28 | 2023-07-14 | 天津键凯科技有限公司 | 一种聚合物修饰抗体类药物的修饰度的测定方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| WO2003070739A1 (en) | 2002-02-19 | 2003-08-28 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| US20060167241A1 (en) | 2003-07-15 | 2006-07-27 | Mitsui Chemicals, Inc. | Method for synthesizing cyclic bisdinucleoside |
| AU2004311702A1 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
| WO2006078752A2 (en) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| WO2008001101A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| EP2342616A2 (en) | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| AU2010330823A1 (en) | 2009-12-18 | 2012-07-05 | Joslin Diabetes Center, Inc. | Beta-cell replication promoting compounds and methods of their use |
| CA2819620A1 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| MX2013006951A (es) | 2010-12-16 | 2013-10-03 | Abbvie Inc | Compuestos antivirales. |
| US9284343B2 (en) | 2011-04-04 | 2016-03-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| JO3154B1 (ar) | 2011-06-17 | 2017-09-20 | Glaxosmithkline Llc | عوامل مضادة لـ trpv4 |
| JP2014530910A (ja) | 2011-10-24 | 2014-11-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | 新規化合物 |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| US9611257B2 (en) | 2012-12-21 | 2017-04-04 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| JP6510485B2 (ja) | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｐｒｍｔ５インヒビターおよびそれらの使用方法 |
| US10087151B2 (en) | 2014-01-09 | 2018-10-02 | The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| WO2015200680A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| SG11201610476VA (en) | 2014-07-01 | 2017-01-27 | Millennium Pharm Inc | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| JP6584521B2 (ja) * | 2015-02-24 | 2019-10-02 | ファイザー・インク | 抗がん剤として有用な置換ヌクレオシド誘導体 |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| PE20181894A1 (es) | 2016-03-10 | 2018-12-11 | Janssen Pharmaceutica Nv | Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5 |
| CN115626935B (zh) | 2016-10-03 | 2025-07-15 | 詹森药业有限公司 | 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物 |
| EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
| CN110382707A (zh) | 2017-02-27 | 2019-10-25 | 詹森药业有限公司 | 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途 |
| IL275129B2 (en) | 2017-12-08 | 2023-10-01 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
-
2017
- 2017-10-02 CN CN202211277466.7A patent/CN115626935B/zh active Active
- 2017-10-02 BR BR112019006414A patent/BR112019006414A2/pt active Search and Examination
- 2017-10-02 EP EP17781060.3A patent/EP3519413A1/en active Pending
- 2017-10-02 US US16/336,934 patent/US11098062B2/en active Active
- 2017-10-02 UA UAA201904546A patent/UA124074C2/uk unknown
- 2017-10-02 AU AU2017338269A patent/AU2017338269B2/en not_active Ceased
- 2017-10-02 MX MX2019003843A patent/MX2019003843A/es unknown
- 2017-10-02 JP JP2019517909A patent/JP7101171B2/ja active Active
- 2017-10-02 TN TNP/2019/000087A patent/TN2019000087A1/en unknown
- 2017-10-02 CA CA3037998A patent/CA3037998A1/en active Pending
- 2017-10-02 MA MA046341A patent/MA46341A/fr unknown
- 2017-10-02 CN CN201780061258.4A patent/CN109803971B/zh active Active
- 2017-10-02 KR KR1020197012099A patent/KR102531344B1/ko active Active
- 2017-10-02 PE PE2019000723A patent/PE20190706A1/es unknown
-
2019
- 2019-03-31 IL IL265718A patent/IL265718B/en unknown
- 2019-04-02 MX MX2023005574A patent/MX2023005574A/es unknown
- 2019-04-03 PH PH12019500731A patent/PH12019500731A1/en unknown
-
2021
- 2021-07-16 US US17/378,417 patent/US11993614B2/en active Active
-
2022
- 2022-03-04 JP JP2022033419A patent/JP7576587B2/ja active Active
-
2023
- 2023-10-17 US US18/488,626 patent/US20240124493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7576587B2 (ja) | 2024-10-31 |
| KR102531344B1 (ko) | 2023-05-10 |
| CA3037998A1 (en) | 2018-04-12 |
| MX2023005574A (es) | 2023-05-29 |
| US20210371433A1 (en) | 2021-12-02 |
| US11993614B2 (en) | 2024-05-28 |
| MX2019003843A (es) | 2019-06-24 |
| US11098062B2 (en) | 2021-08-24 |
| JP7101171B2 (ja) | 2022-07-14 |
| IL265718B (en) | 2021-08-31 |
| BR112019006414A2 (pt) | 2019-06-25 |
| TN2019000087A1 (en) | 2020-07-15 |
| US20190263833A1 (en) | 2019-08-29 |
| CN109803971A (zh) | 2019-05-24 |
| JP2019534255A (ja) | 2019-11-28 |
| EP3519413A1 (en) | 2019-08-07 |
| UA124074C2 (uk) | 2021-07-14 |
| CN109803971B (zh) | 2022-10-28 |
| PH12019500731A1 (en) | 2019-06-24 |
| US20240124493A1 (en) | 2024-04-18 |
| JP2022084699A (ja) | 2022-06-07 |
| CN115626935B (zh) | 2025-07-15 |
| IL265718A (en) | 2019-05-30 |
| AU2017338269B2 (en) | 2021-03-25 |
| KR20190056425A (ko) | 2019-05-24 |
| CN115626935A (zh) | 2023-01-20 |
| AU2017338269A1 (en) | 2019-04-04 |
| PE20190706A1 (es) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46341A (fr) | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 | |
| EP3389557A4 (en) | Transseptal delivery system | |
| EP3860888A4 (en) | ACTUATED ATOMIZATION SYSTEM | |
| EP3435978A4 (en) | RELEASE SYSTEM | |
| EP3344644A4 (en) | CYCLIC DI NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| MA45013A (fr) | Système d'affichage tête haute | |
| MA42032A (fr) | Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac | |
| EP3361958A4 (en) | GLOBAL SPINAL ALIGNMENT PROCESS | |
| EP3356856A4 (en) | MONITORING BASED ON EXTENSIVE CHECK FOR IMPROVED GUIDANCE QUALITY | |
| EP3308212C0 (en) | BEAM DIRECTOR | |
| EP3299002A4 (en) | walking assistance device | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| IT201700070755A1 (it) | “sistema di separazione” | |
| EP3377520A4 (en) | METHOD FOR EXTENDING THE HALF TIME OF A PROTEIN | |
| MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| EP3328227A4 (en) | COMPRESSIVE DAMPING SYSTEM FOR HEAD PROTECTION | |
| EP3344326A4 (en) | DEVICE FOR INTRAOSSARY INJECTION | |
| EP3395601A4 (en) | HEAD-UP DISPLAY SYSTEM FOR VEHICLES | |
| EP3446174A4 (en) | RELIABILITY VERIFICATION OF A PORTABLE DISPLAY | |
| KR101556284B9 (ko) | Gps를 기반으로 한 지하시설물의 측량시스템 | |
| EP3529947A4 (en) | INTERFACE SYSTEM | |
| EP3397993A4 (en) | DATA CONTROLLED CLOCK DEVIATION SETTING | |
| EP3354128A4 (en) | IRRIGATION SYSTEM | |
| EP3359994A4 (en) | SELF-DRIVE SYSTEM | |
| DK3275211T3 (da) | Fremgangsmåde til drift af et elektroakustisk system samt et elektroakustisk system |